Innovative Oncology Focus NETRIS Pharma specializes in developing first-in-class therapeutics targeting cancer, particularly focusing on Netrin-1 and tumor progression pathways. Their emphasis on cutting-edge cellular mechanism research presents opportunities for collaborations in advanced cancer treatments and personalized medicine approaches.

Strategic Partnerships and Recognition The company’s recent attendance at major events like ESMO Congress 2025 and receipt of awards such as the Best Biotech Pitch highlight its growing influence and credibility in the biotech space, opening doors for strategic alliances, joint ventures, and investor engagement.

Expansion into Endometriosis Launching a development program in endometriosis along with securing €3.9 million in funding demonstrates diversification beyond oncology, which could be a promising avenue for sales of research tools, diagnostics, or complementary therapeutics in inflammatory diseases.

Funding and Growth Potential With recent funding of over €8 million and ongoing clinical-stage development, NETRIS Pharma is positioned for accelerated growth, creating opportunities for sales of medical devices, laboratory supplies, or biochemical reagents aligned with their clinical research initiatives.

Technological and Scientific Collaboration As an integrated biotech within a prominent cancer research center in Lyon, NETRIS Pharma offers opportunities for scientific collaboration, licensing of proprietary technologies, or joint research programs that can enhance product pipelines or expand market reach.